Parkinson’s disease(PD), the second most common neurodegenerative disorder, is likely to become more prevalent as the average age of the population increases. Although there are several palliative therapies for PD, there are no clinically available disease-modifying treatments. It is reasonable to explore novel methods for targeting neuroinflammation and providing neuroprotection in PD. Here we sought to use colostrum milk extracellular vesicles(C-EVs) as a nutraceutical agent to downregulate ne